You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 115 No. 9, September 1989 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Efficacy of Oral Ciprofloxacin Plus Rifampin for Treatment of Malignant External Otitis

Jennifer Rubin, MD; Gary Stoehr, PharmD; Victor L. Yu, MD; Robert R. Muder, MD; Akbar Matador, MD; Donald B. Kamerer, MD

Arch Otolaryngol Head Neck Surg. 1989;115(9):1063-1069.


Abstract

• Malignant external otitis is an invasive pseudomonal infection characteristically afflicting the elderly patient with diabetes mellitus. Therapy has traditionally consisted of the long-term administration of combination parenteral antibiotics, but morbidity and mortality remain substantial despite this therapy. We treated 11 consecutive patients with the oral combination of ciprofloxacin (750 mg twice daily) and rifampin (600 mg twice daily) for 6 to 12 weeks (mean, 8 weeks). Pseudomonas aeruginosa was isolated from ear canal or mastoid, and bone destruction was documented by computed tomography in all patients. Seven patients (64%) had ear irrigation before onset of the infection. Ten patients fulfilled the criteria of both clinical and bacteriologic cure. No serious adverse reaction to either antibiotic was observed. Otalgia and otorrhea responded at a mean of 6 and 4 days, respectively, following the initiation of therapy. The erythrocyte sedimentation rate fell from a mean pretherapy value of 81 mm/h (range, 41 to 138 mm/h) to 18 mm/h (range, 3 to 45 mm/h) after the completion of antibiotic therapy. Minimum inhibitory and bactericidal concentrations established that all organisms were sensitive to ciprofloxacin. Time-kill curve and checkerboard assays failed to demonstrate either synergy or antagonism between ciprofloxacin and rifampin. Serum inhibitory and bactericidal titers showed minimal increase in inhibition and killing of the bacteria with the addition of rifampin. Rifampin did not alter the pharmacokinetics of ciprofloxacin. The successful use of oral antibiotics for this difficult infection may be a major advance. Reduction in antibiotic costs and hospitalization and convenience of oral administration were of notable benefit.

(Arch Otolaryngol Head Neck Surg. 1989;115:1063-1069)



Author Affiliations

From the Departments of Otolaryngology (Drs Rubin, Matador, and Kamerer), Medicine (Drs Yu and Muder), and Pharmacy Practice (Dr Stoehr), University of Pittsburgh (Pa).


Footnotes

Accepted for publication March 28, 1989.

Reprint requests to University of Pittsburgh School of Medicine, 968 Scaife Hall, Pittsburgh, PA 15261 (Dr Yu).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Adjuvant Hyperbaric Oxygen in Malignant External Otitis
Davis et al.
Arch Otolaryngol Head Neck Surg 1992;118:89-93.
ABSTRACT  

Caution Indicated in Prescribing Ciprofloxacin
PICKARD
Arch Otolaryngol Head Neck Surg 1990;116:742-742.
ABSTRACT  

Otolaryngology--Head and Neck Surgery
Stiernberg
JAMA 1990;263:2669-2671.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1989 American Medical Association. All Rights Reserved.